EA201791732A1 - Безопасное введение десмопрессина - Google Patents

Безопасное введение десмопрессина

Info

Publication number
EA201791732A1
EA201791732A1 EA201791732A EA201791732A EA201791732A1 EA 201791732 A1 EA201791732 A1 EA 201791732A1 EA 201791732 A EA201791732 A EA 201791732A EA 201791732 A EA201791732 A EA 201791732A EA 201791732 A1 EA201791732 A1 EA 201791732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
desmopressin
treatment
desmopressina
safe
diuresis
Prior art date
Application number
EA201791732A
Other languages
English (en)
Russian (ru)
Inventor
Сеймор Файн
Original Assignee
Серенити Фармасьютикалз, Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42168193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Серенити Фармасьютикалз, Элэлси filed Critical Серенити Фармасьютикалз, Элэлси
Publication of EA201791732A1 publication Critical patent/EA201791732A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A61M15/085—Fixing means therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
EA201791732A 2008-12-22 2009-12-21 Безопасное введение десмопрессина EA201791732A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13987108P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
EA201791732A1 true EA201791732A1 (ru) 2018-03-30

Family

ID=42168193

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791732A EA201791732A1 (ru) 2008-12-22 2009-12-21 Безопасное введение десмопрессина
EA201170873A EA028531B1 (ru) 2008-12-22 2009-12-21 Безопасный способ введения десмопрессина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201170873A EA028531B1 (ru) 2008-12-22 2009-12-21 Безопасный способ введения десмопрессина

Country Status (19)

Country Link
US (4) US20120015880A1 (cg-RX-API-DMAC7.html)
EP (2) EP2381923B2 (cg-RX-API-DMAC7.html)
JP (4) JP5731396B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170081711A (cg-RX-API-DMAC7.html)
CN (2) CN105963834A (cg-RX-API-DMAC7.html)
AU (1) AU2009330203B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923557A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747998C (cg-RX-API-DMAC7.html)
DK (1) DK2381923T4 (cg-RX-API-DMAC7.html)
EA (2) EA201791732A1 (cg-RX-API-DMAC7.html)
ES (1) ES2692345T5 (cg-RX-API-DMAC7.html)
IL (1) IL213699A (cg-RX-API-DMAC7.html)
MX (1) MX2011006765A (cg-RX-API-DMAC7.html)
NZ (1) NZ593613A (cg-RX-API-DMAC7.html)
PL (1) PL2381923T5 (cg-RX-API-DMAC7.html)
PT (1) PT2381923T (cg-RX-API-DMAC7.html)
SG (2) SG10201509152VA (cg-RX-API-DMAC7.html)
WO (1) WO2010075266A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105420B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) * 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
EP3024473A1 (en) 2013-07-23 2016-06-01 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CA2967390A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS171787B1 (cg-RX-API-DMAC7.html) 1973-11-09 1976-11-29
US4148787A (en) 1976-05-24 1979-04-10 Ferring Ab Antidiuretically effective polypeptide and a process for preparing the same
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4944429A (en) 1987-08-28 1990-07-31 Schering Corporation Manually-operable spray dispenser with locking mechanism
US5154122A (en) 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
CN1060980A (zh) * 1990-10-26 1992-05-13 蔡东林 多用电控自控微型喷雾器
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DK0708657T3 (da) * 1993-06-29 2001-10-15 Ferring Bv Sammensætninger til nasal administration af desmopression
WO1996040332A1 (en) * 1995-06-07 1996-12-19 O'neil, Christine Patient controlled drug delivery device
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
AU3421600A (en) 1999-02-14 2000-08-29 Ing. Erich Pfeiffer Gmbh Dispenser for flowable media
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
DE10110742A1 (de) 2001-02-28 2002-09-05 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
PL200833B1 (pl) 2001-09-21 2009-02-27 Pfeiffer Erich Gmbh & Co Kg Dozownik z pojemnikiem aplikowanego środka oraz pompka do dozownika
US20030232078A1 (en) 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2005046707A1 (en) * 2003-11-10 2005-05-26 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
JP2007513199A (ja) * 2003-12-08 2007-05-24 ベントレー ファーマスーティカルス,インコーポレイテッド インスリン治療のための薬学的組成物及び方法
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
CN1785448A (zh) * 2005-11-11 2006-06-14 广东工业大学 医用防染式药雾吸入喷嘴
EP2035031A4 (en) * 2006-06-08 2010-02-24 Cpex Pharmaceuticals Inc INSULIN COMPOSITION
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration

Also Published As

Publication number Publication date
JP2015127350A (ja) 2015-07-09
KR101755042B1 (ko) 2017-07-06
EA201170873A1 (ru) 2012-02-28
JP5959076B2 (ja) 2016-08-02
JP5731396B2 (ja) 2015-06-10
JP2012513403A (ja) 2012-06-14
AU2009330203A1 (en) 2011-07-14
IL213699A (en) 2016-05-31
DK2381923T4 (da) 2023-09-11
ZA201105420B (en) 2012-04-25
JP2016196488A (ja) 2016-11-24
CA2747998C (en) 2016-05-31
CN105963834A (zh) 2016-09-28
EA028531B1 (ru) 2017-11-30
CN102355888A (zh) 2012-02-15
EP2381923A2 (en) 2011-11-02
JP6389209B2 (ja) 2018-09-12
SG10201509152VA (en) 2015-12-30
PL2381923T3 (pl) 2019-04-30
ES2692345T3 (es) 2018-12-03
MX2011006765A (es) 2011-11-01
KR20170081711A (ko) 2017-07-12
JP2018184407A (ja) 2018-11-22
PL2381923T5 (pl) 2024-08-26
NZ593613A (en) 2013-02-22
EP2381923B2 (en) 2023-06-07
CA2747998A1 (en) 2010-07-01
EP2381923B1 (en) 2018-08-01
US20200078542A1 (en) 2020-03-12
SG172344A1 (en) 2011-07-28
ES2692345T5 (es) 2024-01-26
US20120015880A1 (en) 2012-01-19
WO2010075266A3 (en) 2011-01-06
KR20110102915A (ko) 2011-09-19
BRPI0923557A2 (pt) 2016-01-26
IL213699A0 (en) 2011-07-31
WO2010075266A2 (en) 2010-07-01
US20240342407A1 (en) 2024-10-17
AU2009330203B2 (en) 2015-09-03
DK2381923T3 (en) 2018-11-19
EP3437633A1 (en) 2019-02-06
US20220126039A1 (en) 2022-04-28
PT2381923T (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
MX2012000066A (es) Administracion segura de desmopresina.
EA201170873A1 (ru) Безопасное введение десмопрессина
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
NZ701038A (en) Treating acute decompensated heart failure with relaxin
ZA201201060B (en) Combination of an oxidant,a photosensitizer and a wound healing agent for oral disinfection and treatment or oral disease
NZ593653A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
TN2011000217A1 (en) Pirfenidone treatment for patients with atypical liver fuction
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2013005725A (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
MX2011013296A (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
PH12014501629A1 (en) Treatment of cognitive disorders with (r)-7- chloro -n- (quinuclidin -3-yl) benzo[b] thiophene -2- carboxamide and pharmaceutically acceptable salts thereof
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
MX355015B (es) Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.
NZ596218A (en) Bssl antagonists for treatment of inflammatory diseases